[go: up one dir, main page]

ECSP12011618A - Procedimiento para la elaboración de un jarabe farmacéutico-veterinario que comprende omeprazol - Google Patents

Procedimiento para la elaboración de un jarabe farmacéutico-veterinario que comprende omeprazol

Info

Publication number
ECSP12011618A
ECSP12011618A ECSP12011618A ECSP12011618A EC SP12011618 A ECSP12011618 A EC SP12011618A EC SP12011618 A ECSP12011618 A EC SP12011618A EC SP12011618 A ECSP12011618 A EC SP12011618A
Authority
EC
Ecuador
Prior art keywords
syrup
pharmaceutical
omeprazol
veterinary
understands
Prior art date
Application number
Other languages
English (en)
Inventor
Erik Juvonen
Louis Massimo Micolucci
Original Assignee
Vetegen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43465734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011618(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vetegen Llc filed Critical Vetegen Llc
Publication of ECSP12011618A publication Critical patent/ECSP12011618A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una disolución farmacéutica o formulación de jarabe que comprende; ompetrazol, un agente solubilizante, un agente edulcorante, un agente aromatizante y un antioxidante.
ECSP12011618 2009-07-20 2012-01-20 Procedimiento para la elaboración de un jarabe farmacéutico-veterinario que comprende omeprazol ECSP12011618A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22689009P 2009-07-20 2009-07-20

Publications (1)

Publication Number Publication Date
ECSP12011618A true ECSP12011618A (es) 2012-04-30

Family

ID=43465734

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011618 ECSP12011618A (es) 2009-07-20 2012-01-20 Procedimiento para la elaboración de un jarabe farmacéutico-veterinario que comprende omeprazol

Country Status (11)

Country Link
US (1) US8530500B2 (es)
EP (1) EP2456439A4 (es)
JP (1) JP2012533633A (es)
AU (1) AU2010276404A1 (es)
CA (1) CA2768024A1 (es)
CL (1) CL2012000169A1 (es)
CO (1) CO6491061A2 (es)
EC (1) ECSP12011618A (es)
IN (1) IN2012DN00359A (es)
PE (1) PE20120781A1 (es)
WO (1) WO2011011351A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402796SA (en) * 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
GB201306720D0 (en) 2013-04-12 2013-05-29 Special Products Ltd Formulation
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
GB2561355A (en) * 2017-04-10 2018-10-17 Eaststone Ltd Pharmaceutical composition and a method for manufacturing the same
CN107397719A (zh) * 2017-08-16 2017-11-28 洛阳市兽药厂 一种畜禽用奥美拉唑可溶性粉剂及其制备工艺
JP7515092B2 (ja) * 2017-10-18 2024-07-12 北海道公立大学法人 札幌医科大学 抗菌剤のスクリーニング方法
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
GB2616663A (en) * 2022-03-18 2023-09-20 Alkaloid Ad Skopje Pharmaceutical formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
CA2362932C (en) * 1999-02-23 2010-11-30 Merck & Co., Inc. Pharmaceutical composition containing proton pump inhibitors
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
JP2007532677A (ja) 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation

Also Published As

Publication number Publication date
US8530500B2 (en) 2013-09-10
US20110015233A1 (en) 2011-01-20
WO2011011351A3 (en) 2011-05-19
PE20120781A1 (es) 2012-06-27
IN2012DN00359A (es) 2015-05-22
JP2012533633A (ja) 2012-12-27
CL2012000169A1 (es) 2012-08-31
CA2768024A1 (en) 2011-01-27
WO2011011351A2 (en) 2011-01-27
CO6491061A2 (es) 2012-07-31
EP2456439A4 (en) 2012-12-26
EP2456439A2 (en) 2012-05-30
AU2010276404A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
ECSP12011618A (es) Procedimiento para la elaboración de un jarabe farmacéutico-veterinario que comprende omeprazol
CR20110110A (es) Composicion farmaceutica
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
ECSP10010295A (es) Formulacion de anticuerpo
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
EA201791299A1 (ru) Микроинкапсулированные композиции каннабиноидов
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
BR112015014902A2 (pt) montagem de empacotamento para dispositivos de entrega de fármaco
ECSP10010622A (es) Composición farmacéutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
MA32934B1 (fr) Combinaisons inhibitrices hsp90
MX2013006644A (es) Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina.
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2014003121A1 (es) Formulacion liquida que comprende propilenglicol y un inodilatador, un inhibidor de la enzima convertidora de angiotensina o una combinacion de ambos; proceso para prepararla; kit; y metodo de tratamiento de una enfermedad cardiaca y/o hipertension.
ECSP12012208A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
EP2865522A4 (en) LAMINATE AND PACKAGING AND PACKAGING THEREOF
AR098168A1 (es) Formulación estable de insulina glulisina
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
CR11744A (es) Formulacion liquida para deferiprona con gusto agradable al paladar
ECSP11011307A (es) Comprimidos para terapia de combinacion
CL2015002837A1 (es) Compuestos de piridinilpirazoloquinolina.
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
UY32187A (es) Composiciones farmaceuticas topicas
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
AR086689A1 (es) Auxiliar de la formulacion para la desinfeccion de semillas